Loss of heterozygosity at the FHIT gene in different solid human tumours and its association with survival in colorectal cancer patients

Anticancer Research

Volumn 22, Issue 6 A, 2002, Pages 3205-3212

  Petursdottir, Thorgunnur Eyfjord ^a   Hafsteinsdottir, Sigridur H ^a   Jonasson, Jon G ^a,b   Moller, Pall H ^a   Thorsteinsdottir, Unnur ^c   Huiping, Chen ^a   Egilsson, Valgardur ^a   Ingvarsson, Sigurdur ^d  

^a LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^b ICELANDIC CANCER REGISTRY   (Iceland)

^c DECODE GENETICS   (Iceland)

^d UNIVERSITY OF ICELAND   (Iceland)

Author keywords

Breakpoint; FHIT; Loss of heterozygosity; Survival; Tumour suppressor gene

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ARTICLE; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; D3S1234 GENE; D3S1300 GENE; D3S1313 GENE; D3S1600 GENE; D3S2757 GENE; D3S4260 GENE; DISEASE ASSOCIATION; DNA FLANKING REGION; GENE EXPRESSION; GENE LOCATION; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; LUNG TUMOR; MARKER GENE; MICROSATELLITE MARKER; PRIORITY JOURNAL; SOLID TUMOR; STATISTICAL SIGNIFICANCE; TUMOR SUPPRESSOR GENE;

ACID ANHYDRIDE HYDROLASES; COLORECTAL NEOPLASMS; FEMALE; GENETIC MARKERS; HUMANS; LOSS OF HETEROZYGOSITY; MALE; NEOPLASM PROTEINS; NEOPLASMS; SURVIVAL RATE;

EID: 0036871168     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, Siprashvili Z, Mori M, McCue P and Druck T: The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinomaassociated t(3:8) breakpoint, is abnormal in digestive tract cancers. Cell 84: 587-597, 1996.
2. Wilke CM, Hall BK, Hoge A, Paradee W, Smith DI and Glover TW: FRA3B extends over a broad region and contains a spontaneous HPV16 integration site: direct evidence for the coincidence of viral integration sites and fragile sites. Hum Mol Genet 5: 187-195, 1996.
3. Barnes LD, Garrison PN, Siprashvili Z, Guranowski A, Robinson AK, Ingram SW, Croce CM, Ohta M and Huebner K: Fhit, a putative tumor suppressor in humans, is a dinucleoside 5′,5‴-P1,P3triphosphate hydrolase. Biochemistry 35: 11529-11535, 1996.
4. Siprashvili Z, Sozzi G, Barnes LD, McCue P, Robinson AK, Eryomin V, Sard L, Tagliabue E, Greco A, Fusetti L, Schwartz G, Pierotti MA, Croce CM and Huebner K: Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci USA 94: 13771-13776, 1997.
5. Pace HC, Garrison PN, Robinson AK, Barnes LD, Draganescu A, Rosler A, Blackburn GM, Siprashvili Z, Croce CM, Huebner K and Brenner C: Genetic, biochemichal, and crystallographic characterization of Fhit-substrate complexes as the active signalling form of Fhit. Proc Natl Acad Sci USA 95: 5484-5489, 1998.
6. Ingvarsson S, Agnarsson BA, Sigbjornsdottir BI, Kononen J, Kallioniemi OP, Barkardottir RB, Kovatich AJ, Schwarting R, Hauck WW, Huebner K and McCue PA: Reduced Fhit expression in sporadic and BRCA2-linked breast carcinomas. Cancer Res 59: 2682-2689, 1999.
7. Huiping C, Jonasson JG, Agnarsson BA, Sigbjornsdottir BI, Huebner K and Ingvarsson S: Analysis of the fragile histidine triad (FHIT) gene in lobular breast cancer. Eur J Cancer 36: 1552-1557, 2000.
8. Ingvarsson S, Sigbjornsdottir BI, Huiping C, Jonasson JG and Agnarsson BA: Alterations of the FHIT gene in breast cancer: association with tumor progression and patient survival. Cancer Detect Prev 25: 318-324, 2001.
9. Zou M, Shi Y, Farid NR, al-Sedairy ST and Paterson MC: FHIT gene abnormalities in both benign and malignant thyroid tumours. Eur J Cancer 35: 467-472, 1999.
10. Menin C, Santacatterina M, Zambon A, Montagna M, Parenti A, Ruol A and D/Andrea E: Anomalous transcripts and allelic deletions of the FHIT gene in human esophageal cancer. Cancer Genet Cytogenet 119: 56-61, 2000.
11. Sozzi G, Sard L, De Gregorio L, Marchetti A, Musso K, Buttitta F, Tornielli S, Pellegrini S, Veronese ML, Manenti G, Incarbone M, Chella A, Angeletti CA, Pastorino U, Huebner K, Bevilaqua G, Pilotti S, Croce CM and Pierotti MA: Association between cigarette smoking and FHIT gene alterations in lung cancer. Cancer Res 57: 2121-2123, 1997.
12. Nelson HH, Wiencke JK, Gunn L, Wain JC, Christiani DC and Kelsey KT: Chromosome 3p14 alterations in lung cancer: evidence that FHIT exon deletions is a target of tobacco carcinogens and asbestos. Cancer Res 58: 1804-1807, 1998.
13. Geradts J, Fong KM, Zimmerman PV and Minna JD: Loss of Fhit expression in non-small-cell lung cancer: correlation with molecular genetic abnormalities and clinicopathological features. Br J Cancer 82: 1191-1197, 2000.
14. Lee SH, Kim WH, Kim HK, Woo KM, Nam HS, Kim HS, Kim JG and Cho MH: Altered expression of the fragile histidine triad gene in primary gastric adenocarcinomas. Biochem Biophys Res Commun 15: 850-855, 2001.
15. Sorio C, Baron A, Orlandini S, Zamboni G, Pederzoli P, Huebner K and Scarpa A: The FHIT gene is expressed in pancreatic ductular cells and is altered in pancreatic cancers. Cancer Res 59: 1308-1314, 1999.
16. Baffa R, Gomella LG, Vecchione A, Bassi P, Mimori K, Sedor J, Calviello CM, Gardiman M, Minimo C, Strup SE, McCue PA, Kovatich AJ, Pagano F, Huebner K and Croce CM: Loss of FHIT expression in transitional cell carcinoma of the urinary bladder. Am J Pathol 156: 419-424, 2000.
17. Wada T, Louhelainen J, Hemminki K, Adolfsson J, Wijkstrom H, Norming U, Borgstrom E, Hansson J and Steineck G: The prevalence of loss of heterozygosity in chromosome 3, including FHIT, in bladder cancer, using the fluorescent multiplex polymerase chain reaction. BJU Int 87: 876-881, 2001.
18. Fullwood P, Marchini S, Rader JS, Martinez A, Macartney D, Broggini M, Morelli C, Barbanti-Brodano G, Maher ER and Latif F: Detailed genetic and physical mapping of tumor suppressor loci on chromosome 3p in ovarian cancer. Cancer Res 59: 4662-4667, 1999.
19. Tanimoto K, Hayashi S, Tsuchiya E, Tokuchi Y, Kobayashi Y, Yoshiga K, Okui T, Kobayashi M and Ichikawa T: Abnormalities of the FHIT gene in human oral carcinogenesis. Br J Cancer 82: 838- 843, 2000.
20. Uzawa N, Akanuma D, Negishi A, Iwaki H, Uzawa Y, Amagasa T and Yoshida MA: Homozygous deletion on the short arm of chromosome 3 in human oral squamous cell carcinomas. Oral Oncol 37: 351-356, 2001.
21. Velickovic M, Delahunt B and Grebe SKG: Loss of heterozygosity at 3p14.2 in clear cell renal cell carcinoma is an early event and is highly localized to the FHIT gene locus. Cancer Res 59: 1323-1326, 1999.
22. Baffa R, Veronese ML, Santoro R, Mandes B, Palozzo JP, Rugge M, Santoro E, Croce CM and Huebner K: Loss of FHIT expression in gastric carcinoma. Cancer Res 58: 4708-4714, 1998.
23. Luceri C, Guglielmi F, De Filippo C, Caderni G, Mini E, Biggeri A, Napoli C, Tonelli F, Cianchi F and Dolara P: Clinicopathologic features and FHIT gene expression in sporadic colorectal adenocarcinomas. Scand J Gastroenterol 35: 637-641, 2000.
24. Negrini M, Monaco C, Vorechovsky I, Ohta M, Druck T, Baffa R, Huebner K and Croce CM: The FHIT gene at 3p14.2 is abnormal in breast carcinomas. Cancer Res 56: 3173-3179, 1996.
25. Kastury K, Baffa R, Druck T, Ohta M, Cotticelli MG, Inoue H, Negrini M, Rugge M, Huang D, Croce CM, Palazzo J and Huebner K: Potential gastrointestinal tumor suppressor locus at the 3p14.2 FRA3B site identified by homozygous deletions in tumor cell lines. Cancer Res 56: 978-983, 1996.
26. Ahmadian M, Wistuba II, Fong KM, Behrens C, Kodagoda DR, Saboorian MH, Shay J, Tomlinson GE, Blum J, Minna JD and Gazdar AF: Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands. Cancer Res 57: 3664-3668, 1997.
27. Inoue H, Ishii H, Alder H, Snyder E, Druck T, Huebner K and Croce CM: Sequence of the FRA3B common fragile region: implications for the mechanism of FHIT deletion. Proc Natl Acad Sci USA 94: 14584-14589, 1997.
28. Druck T, Hadaczek P, Fu TB, Ohta M, Siprashvili Z, Baffa R, Negrini M, Kastury K, Veronese ML, Rosen D, Rothstein J, McCue P, Cotticelli MG, Inoue H Croce CM and Huebner K: Structure and expression of the human FHIT gene in normal and tumor cells. Cancer Res 57: 504-512, 1997.
29. Gemma A, Hagiwara K, Ke Y, Burke LM, Khan MA, Nagashima M, Bennett WP and Harris CC: FHIT mutations in human primary gastric cancer. Cancer Res 57: 1435-1437, 1997.
30. Kannan K, Munirajan AK, Bhuvarahamurthy V, Mohanprasad BK, Shankar P, Tsuchida N and Shanmugam G: FHIT gene mutations and single nucleotide polymorphism in Indian oral and cervical squamous cell carcinomas. Oral Oncol 36: 189-193, 2000.
31. Zochbauer-Muller S, Fong KM, Maitra A, Lam S, Geradts J, Ashfaq R, Virmani AK, Milchrub S, Gazdar AF and Minna JD: 5/CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. Cancer Res 61: 3581-3585, 2001.
32. Sard L, Accornero P, Tornielli S, Delia D, Bunone G, Campiglio M, Colombo MP, Gramegna M, Croce CM, Pierotti MA and Sozzi G: The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and cell cycle control. Proc Natl Acad Sci USA 96: 8489-8492, 1999.
33. Werner NS, Siprashvili Z, Fong LY, Marquitan G, Schroder JK, Bardenheuer W, Seeber S, Huebner K, Schutte J and Opalka B: Differential susceptibility of renal carcinoma cell lines to tumor suppression by exogenous Fhit expression. Cancer Res 60: 2780-2785, 2000.
34. Ji L, Fang B, Yen N, Fong K, Minna JD and Roth JA: Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res 59: 3333-3339, 1999.
35. Ishii H, Dumon KR, Vecchione A, Trapasso F, Mimori K, Alder H, Mori M, Sozzi G, Baffa R, Huebner K and Croce CM: Effect of adenoviral transduction of the fragile histidine triad gene into esophageal cancer cells. Cancer Res 61: 1578-1584, 2001.
36. Kisselev LL, Justesen J, Wolfson AD and Frolova LY: Diadenosine oligophosphates (Ap(n)A), a novel class of signalling molecules? FEBS Lett 427: 157-163, 1998.
37. Zanesi N, Fidanza V, Fong LY, Mancini R, Druck T, Valtieri M, Rudiger T, McCue PA, Croce CM and Huebner K: The tumor spectrum in FHIT-deficient mice. Proc Natl Acad Sci 98: 10250-10255, 2001.
38. Fong LY, Fidanza V, Zanesi N, Lock LF, Siracusa LD, Mancini R, Siprashvili Z, Ottey M, Martin SE, Druck T, McCue PA, Croce CM and Huebner K: Muir-Torre-like syndrome in Fhit-deficient mice. Proc Natl Acad Sci USA 97: 4742-4747, 2000.
39. Dumon KR, Ishii H, Fong LY, Zanesi N, Fidanza V, Mancini R, Vecchione A, Baffa R, Trapasso F, During MJ, Huebner K and Croce CM: FHIT gene therapy prevents tumor development in Fhit- deficient mice. Proc Natl Acad Sci USA 98: 3346-3351, 2001.
40. Smith SA, Easton OF, Evans OGR and Ponder BAJ: Allele losses in the region 17q 12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nature Genet 2: 128-131, 1992.
41. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
42. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163-170, 1960.
43. Huiping C, Kristjansdottir S, Berghorsson JTh, Jonasson JG, Magnusson J, Egilsson V and Ingvarsson S: High frequency of LOH, MSI and abnormal expression of FHIT in gastric cancer. Eur J Cancer 38: 728-735, 2002.
44. Garinis GA, Gorgoulis VG, Mariatos G, Zacharatos P, Kotsinas A, Liloglou T, Foukas P, Kanavaros P, Kastrinakis NG, Vassilakopoulos T, Vogiatzi T, Field JK and Kittas C: Association of allelic loss at the FHIT locus and p53 alterations with tumour kinetics and chromosomal instability in non-small cell lung carcinomas (NSCLCs). J Pathol 193: 55-65, 2001.
45. Sozzi G, Veronese ML, Negrini M, Baffa R, Cotticelli MG, Inoue H, Tornielli S, Pilotti S, De Gregorio L, Pastorino U, Pierotti MA, Ohta M, Huebner K and Croce CM: The FHIT gene 3p14.2 is abnormal in lung cancer. Cell 85: 17-26, 1996.
46. Velickovic M, Delahunt B, Storkel S and Grebe SKG: VHL and FHIT locus loss of heterozygosity is common in all renal cancer morphotypes but differs in pattern and prognostic significance. Cancer Res 61: 4815-4819, 2001.
47. Ozaki K, Enomoto T, Yoshino K, Hongbo S, Nakamura T, Fujita M, Kuragaki C, Sakata M, Kurachi H and Murata Y: fhit alterations in endometrial carcinoma and hyperplasia. Int J Cancer 85: 306-312, 2000.
48. Wistuba II, Behrens C, Virmani AK, Mele G, Milchgrub S, Girard L, Fondon JW, Garner HR, McKay B, Latif F, Lerman MI, Lam S, Gazdar AF and Minna JD: High resolution chromosome 3p allolotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. Cancer Res 60: 1949- 1960, 2000.
49. Turker MS, Gage BM, Rose JA, Elroy D, Ponomareva ON, Stambrook PJ and Tischfield JA: A novel signature mutation for oxidative damage resembles a mutational pattern found commonly in human cancers. Cancer Res 59: 1837-1839, 1999.
50. Burke L, Khan MA, Freedman AN, Gemma A, Rusin M, Guinee DG, Bennett WP, Caporaso NE, Freming MV, Travis WD, Colby TV, Trastek V, Pairolero PC, Tazelaar HD, Midthun DE, Liotta LA and Harris CC: Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer. Cancer Res 58: 2533-2536, 1998.
51. Capuzzi D, Santoro E, Hauck WW, Kovatich AJ, Rosato FE, Baffa R, Huebner K and McCue PA: Fhit expression in gastric adenocarcinoma: correlation with disease stage and survival. Cancer 88: 24-34, 2000.